XNASBFRI
Market cap7mUSD
Dec 23, Last price
1.01USD
1D
3.22%
1Q
-19.84%
IPO
-98.85%
Name
Biofrontera Inc
Chart & Performance
P/E
—
P/S
0.23
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
34m
+18.82%
Net income
-20m
L+3,045.47%
CFO
-25m
L+53.68%
Earnings
Mar 13, 2025
Profile
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 34,071 18.82% | 28,674 18.98% | 24,100 27.86% | ||
Cost of revenue | 56,648 | 51,155 | 50,451 | ||
Unusual Expense (Income) | |||||
NOPBT | (22,577) | (22,481) | (26,351) | ||
NOPBT Margin | |||||
Operating Taxes | 14 | 32 | 56 | ||
Tax Rate | |||||
NOPAT | (22,591) | (22,513) | (26,407) | ||
Net income | (20,131) 3,045.47% | (640) -98.30% | (37,713) 243.25% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 4,507 | 14,021 | 29,938 | ||
BB yield | -105.22% | -72.36% | -23.27% | ||
| Debt | |||||
Debt current | 5,286 | 498 | 6,694 | ||
Long-term debt | 2,299 | 2,194 | |||
Deferred revenue | 2,400 | 9,542 | |||
Other long-term liabilities | 4,247 | 2,863 | 18,503 | ||
Net debt | 6,164 | (27,877) | (20,664) | ||
| Cash flow | |||||
Cash from operating activities | (24,895) | (16,199) | (26,715) | ||
CAPEX | (5) | (38) | (11) | ||
Cash from investing activities | 619 | (5,156) | (11) | ||
Cash from financing activities | 8,411 | 14,021 | 43,191 | ||
FCF | (31,583) | (9,091) | (34,580) | ||
| Balance | |||||
Cash | 1,421 | 27,756 | 24,545 | ||
Long term investments | 2,813 | 2,813 | |||
Excess cash | 29,135 | 26,153 | |||
Stockholders' equity | (99,648) | (79,491) | (78,862) | ||
Invested Capital | 114,751 | 109,979 | 124,939 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 1,546 | 1,057 | 855 | ||
Price | 2.77 -84.89% | 18.33 -87.81% | 150.40 | ||
Market cap | 4,283 -77.89% | 19,377 -84.94% | 128,628 | ||
EV | 10,447 | (8,500) | 107,964 | ||
EBITDA | (21,513) | (21,309) | (25,811) | ||
EV/EBITDA | 0.40 | ||||
Interest | 600 | 195 | 344 | ||
Interest/NOPBT | |||||